# HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria

Study · id `cardio:ct-nct03550859` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03550859](<https://clinicaltrials.gov/study/NCT03550859>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03550859

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 374 participants.

## Technical summary

Registry record NCT03550859. Randomized; no masking; primary purpose treatment. Start 2018-06-05 (actual); primary completion 2021-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 374 participants (planned count; ClinicalTrials.gov record NCT03550859, source copy `cardio:ctgov-nct03550859-2020-12-14`, retrieved 2026-10-26)
- Started: 2018-06-05 (actual) (ClinicalTrials.gov record NCT03550859, source copy `cardio:ctgov-nct03550859-2020-12-14`, retrieved 2026-10-26)
- Primary completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT03550859, source copy `cardio:ctgov-nct03550859-2020-12-14`, retrieved 2026-10-26)
- Completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT03550859, source copy `cardio:ctgov-nct03550859-2020-12-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT03550859, source copy `cardio:ctgov-nct03550859-2020-12-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03550859-2020-12-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria
- Condition: Chronic Kidney Disease
- Condition: Proteinuria
- Intervention (Drug): Telmisartan/Rosuvastatin 40/10mg
- Intervention (Drug): Telmisartan 40mg
- Lead sponsor: Yuhan Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Yuhan Corporation (`cardio:org-yuhan-corporation`)

## Provenance

Content hash: 5fc8f701fcb01792cf720788b5e15ca9fa45306a0245db1e0d0335b0462d849e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
